Pathogenic bacteria, with their innate resistance to drugs, pose a constant threat to human
health and well-being and put a persistent strain on the health care system. Development of …

Introduction The success of the CDK4/6 inhibitor Ibrance™(Palbociclib) as an anticancer
agent inspired and directed more efforts toward the discovery of selective cyclin-dependent …

The essential enzyme cyclin-dependent kinase 2 (CDK2) is a promising target for anticancer
drug development due to its pivotal role in regulating the cell cycle. This study aimed to …

A series of novel mono and bishydrazones each bearing a 2-oxindole moiety along with
substituted phenylaminopropanamide, pyrrolidin-2-one, benzimidazole, diphenylmethane …

Diabetes mellitus is a severe metabolic disorder, which has very high prevalence rate and
resulting into other health devastating complications. Pancreatic insulin resistance and-cell …

Three new unsymmetric isatin bishydrazone compounds; Comp. I, II, III, were synthesized by
the condensation of 3, 5-dichloro-salicylaldehyde, 3-bromo-5-chloro-salicylaldehyde, and 3 …

In the development of novel antidiabetic agents, a novel series of isoxazolidine-isatin
hybrids were designed, synthesized, and evaluated as dual α‐amylase and α-glucosidase …

Breast cancer (BC) is one of the most prevalent malignancies and the major contributor to
cancer mortality in women globally, with a high degree of heterogeneity and a dismal …

Cancer is still a relentless public health issue. Particularly, colorectal cancer is the third most
prevalent cancer in men and the second in women. Moreover, cancer development and …

Breast cancer is a complex and multi-drug resistant (MDR) disease, which could result in the
failure of many chemotherapeutic clinical agents. Discovering effective molecules from …